Right. We take all of the data we've collected and begin to go after specific reactions that we think are genetically mediated. We found three in the first six months, and we stopped looking at our data. We are still collecting and accumulating data, but we have a limited budget and limited resources. So we've concentrated on bringing these first three into a solution approach.
Instead of continuing to show a link between the drugs and genes, we're trying to bring these into a viable safety solution strategy for clinicians and patients who use those particular medications. So we started with serious morbidity, mortality reactions, drugs that are used in millions of patients a year, and risks that are at least threefold or more higher because of this gene trait.